Skip to main content

Table 3 Clinical course of gefitinib-responders

From: Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

Clinical course No. of patient
Maintain PR and still continue 3
Cessation by patient's will during PR 2
Disease progression (PD) 22
   Insistence to continue 4
   Resumption 4
   Rechallenge 6
   Cessation of gefitinib by PD and no therapy 8